Product Update:

eslicarbazepine acetate 200mg and 800mg tablets and oral suspension 50mg/mL (Zebinix®)  

SMC2087  

Eisai Ltd  

10 August 2018 (Issued 11 January 2019)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

eslicarbazepine acetate (Zebinix®) is accepted for restricted use within NHSScotland.

**Indication under review:** as adjunctive therapy in adolescents and children aged above 6 years with partial-onset seizures with or without secondary generalisation.

**SMC restriction:** patients with highly refractory epilepsy who have been heavily pre-treated and remain uncontrolled with existing anti-epileptic drugs.

SMC has previously accepted eslicarbazepine acetate for restricted use as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.

**Advice context:**

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 14 June 2018.

**Chairman**  
Scottish Medicines Consortium